- HOME >
- GRADUATE >
- Human Sciences >
Clinical Pharmacology and Therapeutics
| Master's Program | Human Sciences, Graduate School of Medicine |
|---|---|
| Doctor's Program | Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology |
| Professor | NAITO Takafumi |
|---|---|
| Associate Professor | HIRAI Keita |
E-mail ： naitou(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.
Our department creates the drug information for implementing the rational pharmacotherapy in clinical settings. For the goal, we develop the quantitative methods of drugs in human biological samples using a liquid chromatograph coupled to mass spectrometer. The present projects quantitatively evaluate the inter-individual variations in clinical responses to drugs from the viewpoints of pharmacokinetics and pharmacodynamics. We finally aim to construct the rational pharmacotherapy based on the factors related to the clinical responses to drugs for each disease and its condition. Our recent attempts are to detect the unknown adverse events and drug-drug interactions using non-experimental methods.
Development of quantitative methods of drugs in human biological samples
We develop the quantitative methods of drugs in human biological samples using an ultra-high performance liquid chromatography and liquid chromatography coupled to mass spectrometer. Our methods are validated to apply to clinical samples according to international guidance. Our department recently puts effort into the development of rapid quantitation of biomedicines including antibody drug in human serum.
Evaluation of inter-individual variation in clinical responses to drugs
Our researches aim to identify determinants/factors that can be used in day-to-day practice to support treatment decisions. We attempt the evaluations of patient data on factors related to the pharmacokinetics, drug efficacy, and adverse reactions observed in clinical settings. Our department recently puts effort into the evaluation of inter-individual variation in clinical responses to drugs at inflammatory conditions and during the perinatal period.
Construction of rational pharmacotherapy for the disease and its conditions
Our researches focus on optimizing pharmacotherapy and pharmaceutical care to the individual patient. Clarification of patient factors related to the pharmacokinetics, drug efficacy, and adverse reactions leads to the construction of rational pharmacotherapy. We aim to construct the rational pharmacotherapy for the disease and its conditions.
Detection of unknown adverse events and drug-drug interactions using non-experimental methods
We aim to detect the unknown adverse events and drug-drug interactions using non-experimental methods. For the goal, our department uses the medical information system in Shinshu University Hospital and the Japanese Adverse Drug Event Report Database. Our pharmacoepidemiological studies using non-experimental methods potentially contribute to the promotion of appropriate and safety use of pharmaceutical products.
1. Nakatsugawa E, Naito T, Shibata K, Kitajima R, Kawakami J. Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics. Fundam Clin Pharmacol. 2024;38(3):596–605
2. Watanabe H, Hirai K, Nakazawa Y, Koike A, Tsuchiya H, Naito T. Effect of Enoxaparin and Daikenchuto coadministration on hepatic disorder markers in gynecological cancer patients after abdominal surgery. Biol Pharm Bull. 2024;47:758–763
3. Miyadera Y, Yamada T, Imoto Y, Yagi T, Naito T, Kawakami J. Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity. J Infect Chemother. 2023;29(2):119–125
4. Nakatsugawa E, Naito T, Imoto Y, Shibata K, Ono T, Kawakami J. Characterization of endogenous markers of hepatic function in patients receiving itraconazole treatment for prophylaxis of deep mycosis. J Infect Chemother. 2023;29(3):244–249
5. Suzuki Y, Naito T, Shibata K, Hosokawa S, Kawakami J. Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia progression status and clinical responses in head and neck cancer patients. Cancer Chemother Pharmacol. 2023;91(6):481–490
6. Itoh H, Yamashita N, Kamijo S, Masuda K, Kato H, Yamaori S. Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023;382:110644
7. Abe K, Shibata K, Naito T, Otsuka A, Karayama M, Maekawa M, Miyake H, Suda T, Kawakami J. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients. Eur J Clin Pharmacol. 2022;78:77–87
8. Taguchi R, Naito T, Suzuki K, Kurosawa Y, Itoh H, Kawakami K. Maternal plasma and cord blood concentration profiles of duloxetine during the peripartum period and their associations with the modified Finnegan score. Ther Drug Monit. 2022;44:351–352
9. Matsuo J, Yamaori S. Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system. J Clin Pharm Ther. 2022;47:70–80
10. Mochizuki T, Shibata K, Naito T, Shimoyama K, Ogawa N, Maekawa M, Kawakami J. LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification. J Pharm Anal. 2022;12(6):852–859
